The hemorrhagic stroke initiative aims to extend and improve patients’ lives 

This American Heart Association® initiative, sponsored by Portola Pharmaceuticals, addresses the need for improved identification and treatment of hemorrhagic stroke patients.

Set to launch later this year, the Hemorrhagic Stroke Initiative will evaluate new efforts to enhance the care of hemorrhagic stroke patients in hospitals and stroke centers across America.

Stroke is the No. 5 cause of death in the United States and a leading cause of disability. Hemorrhagic strokes make up roughly 10 percent of the nearly 800,000 strokes that occur annually, and they have a higher mortality rate than other types of stroke. Hemorrhagic stroke patients who are treated with novel oral anticoagulants, or NOACs, have an in-hospital mortality rate of 26.5%.


Built on the foundation of Get With The Guidelines®

Get With The Guidelines is a hospital-based quality improvement program from the American Heart Association that provides tools and resources to increase adherence to the latest research-based guidelines. GWTG is based on the premise that when medical professionals apply the most up-to-date evidence-based treatment guidelines, patient outcomes improve.  

Phase one will include a select group of hospitals and stroke centers across the nation.

“Hemorrhagic stroke may not be the most common form of stroke, but it is responsible for more than half of the death and disability around stroke,” said Lee H. Schwamm, M.D., executive vice-chairman of neurology and director of the MGH Comprehensive Stroke Center at Massachusetts General Hospital, chair of the American Stroke Association Advisory Council and a volunteer expert for the American Heart Association and the American Stroke Association. “Addressing the treatment for these patients will save lives, improve outcomes and reduce the burden of illness.”